Skip to main content
Erschienen in: American Journal of Clinical Dermatology 6/2004

01.12.2004 | Current Opinion

Topical Therapy for Dermatophytoses

Should Corticosteroids be Included?

verfasst von: Dr Zulal Erbagci

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 6/2004

Einloggen, um Zugang zu erhalten

Abstract

Dermatophytoses, commonly known as ringworm or tinea, represent superficial fungal infections caused by dermatophytes, which are among the most common infections encountered in medicine. The use of corticosteroid-containing combinations in dermatophyte infections that are usually treated with topical medications is still a much-debated issue. The addition of a corticosteroid to local antifungal therapy may be of value in reducing local inflammatory reaction and thus carries the theoretical advantage of rapid symptom relief in acute dermatophyte infections associated with heavy inflammation. However, the use of such combinations requires caution as they have some potential risks, especially with long-term use under occlusive conditions. Corticosteroid-induced cutaneous adverse effects have been reported primarily in pediatric patients due to inappropriate application of these preparations on diaper areas. Additionally, the corticosteroid component may interfere with the therapeutic actions of the antifungal agent, or fungal growth may accelerate because of decreased local immunologic host reaction, such that underlying infection may persist, and dermatophytes may even acquire the ability to invade deeper tissues.
Analysis of the literature documenting clinical study data and adverse reactions related to combination therapy, drew the following conclusions: (i) combination products containing a low potency nonfluorinated corticosteroid may initially be used for symptomatic inflamed lesions of tinea pedis, tinea corporis, and tinea cruris, in otherwise healthy adults with good compliance; (ii) therapy should be substituted by a pure antifungal agent once symptoms are relieved, and should never exceed 2 weeks for tinea cruris and 4 weeks for tinea pedis/ corporis; and (iii) contraindications for the use of these combinations include application on diaper or other occluded areas and facial lesions, as well as in children <12 years of age and in immunosuppressed patients for any reason.
Literatur
1.
Zurück zum Zitat Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev 1995; 8 (2): 240–59PubMed Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev 1995; 8 (2): 240–59PubMed
2.
Zurück zum Zitat Weinstein A, Berman B. Topical treatment of common superficial tinea infections. Am Fam Physician 2002 May 15; 65: 2095–102 Weinstein A, Berman B. Topical treatment of common superficial tinea infections. Am Fam Physician 2002 May 15; 65: 2095–102
3.
Zurück zum Zitat Rippon JW. Medical mycology: the pathogenic fungi and pathogenic actinomycetes. 3rd ed. Philadelphia (PA): WB Saunders Company, 1988: 169–275 Rippon JW. Medical mycology: the pathogenic fungi and pathogenic actinomycetes. 3rd ed. Philadelphia (PA): WB Saunders Company, 1988: 169–275
4.
Zurück zum Zitat Wagner DK, Sohnle PG. Cutaneous defenses against dermatophytes and yeasts. Clin Microbiol Rev 1995; 8: 317–35PubMed Wagner DK, Sohnle PG. Cutaneous defenses against dermatophytes and yeasts. Clin Microbiol Rev 1995; 8: 317–35PubMed
5.
Zurück zum Zitat Elewski B, Sullivan J. Dermatophytes as opportunistic pathogens. J Am Acad Dermatol 1994; 30: 1021–2PubMedCrossRef Elewski B, Sullivan J. Dermatophytes as opportunistic pathogens. J Am Acad Dermatol 1994; 30: 1021–2PubMedCrossRef
6.
Zurück zum Zitat Smith KJ, Welsh M, Skelton H. Trichophyton rubrum showing deep dermal invasion directly from the epidermis in immunosuppressed patients. Br J Dermatol 2001; 145: 344–8PubMedCrossRef Smith KJ, Welsh M, Skelton H. Trichophyton rubrum showing deep dermal invasion directly from the epidermis in immunosuppressed patients. Br J Dermatol 2001; 145: 344–8PubMedCrossRef
7.
Zurück zum Zitat Chastain MA, Reed RJ, Pankey GA. Deep dermatophytosis: report of 2 cases and review of the literature. Cutis 2001; 67: 457–62PubMed Chastain MA, Reed RJ, Pankey GA. Deep dermatophytosis: report of 2 cases and review of the literature. Cutis 2001; 67: 457–62PubMed
8.
Zurück zum Zitat Radentz WH, Yanase DJ. Papular lesions in an immunocompromised patient. Arch Dermatol 1993; 129: 1189–90PubMedCrossRef Radentz WH, Yanase DJ. Papular lesions in an immunocompromised patient. Arch Dermatol 1993; 129: 1189–90PubMedCrossRef
9.
Zurück zum Zitat Erbagci Z. Deep dermatophytoses in association with atopy and diabetes mellitus: Majocchi!!!2019;s granuloma tricophyticum or dermatophytic pseudomycetoma? Mycopathologia 2002; 154: 163–9PubMedCrossRef Erbagci Z. Deep dermatophytoses in association with atopy and diabetes mellitus: Majocchi!!!2019;s granuloma tricophyticum or dermatophytic pseudomycetoma? Mycopathologia 2002; 154: 163–9PubMedCrossRef
10.
Zurück zum Zitat Abraham AG, Kulp-Shorten CL, Callen JP. Remember to consider dermatophyte infection when dealing with recalcitrant dermatoses. South Med J 1998; 91: 349–53PubMedCrossRef Abraham AG, Kulp-Shorten CL, Callen JP. Remember to consider dermatophyte infection when dealing with recalcitrant dermatoses. South Med J 1998; 91: 349–53PubMedCrossRef
11.
Zurück zum Zitat Demidovich CW, Kornfeld BW, Gentry RH, et al. Deep dermatophyte infection with draining nodules in an immunocompromised patient. Cutis 1995; 55: 237–40PubMed Demidovich CW, Kornfeld BW, Gentry RH, et al. Deep dermatophyte infection with draining nodules in an immunocompromised patient. Cutis 1995; 55: 237–40PubMed
12.
Zurück zum Zitat Okuwa T, Horio T. The inhibitory effect of PUVA on the immunity of experimental dermatophytosis in guinea pigs. Arch Dermatol Res 1986; 278: 320–3PubMedCrossRef Okuwa T, Horio T. The inhibitory effect of PUVA on the immunity of experimental dermatophytosis in guinea pigs. Arch Dermatol Res 1986; 278: 320–3PubMedCrossRef
13.
Zurück zum Zitat Jones HE. The atopic-dermatophytosis syndrome. Acta Derm Venereol Suppl 1980; 92: 81–5 Jones HE. The atopic-dermatophytosis syndrome. Acta Derm Venereol Suppl 1980; 92: 81–5
14.
Zurück zum Zitat Tagami H, Kudoh K, Takematsu H. Inflammation and immunity in dermatophytosis. Dermatologica 1989; 179 Suppl. 1: 1–8PubMedCrossRef Tagami H, Kudoh K, Takematsu H. Inflammation and immunity in dermatophytosis. Dermatologica 1989; 179 Suppl. 1: 1–8PubMedCrossRef
15.
Zurück zum Zitat Stahl D, Svejgaard E. Lymphocyte transformation in vitro in acute dermatophytosis: a follow-up study. Acta Derm Venereol 1982; 69: 289–93 Stahl D, Svejgaard E. Lymphocyte transformation in vitro in acute dermatophytosis: a follow-up study. Acta Derm Venereol 1982; 69: 289–93
16.
Zurück zum Zitat Jones HE. Immune response and host resistance of humans to dermatophyte infections. J Am Acad Dermatol 1993; 28: S12–18CrossRef Jones HE. Immune response and host resistance of humans to dermatophyte infections. J Am Acad Dermatol 1993; 28: S12–18CrossRef
17.
Zurück zum Zitat Braathen LR, Kaman T. Human epidermal Langerhans cells induce cellular immune response to trichophytin response in dermatophytosis. Br J Dermatol 1983; 109: 295–300PubMedCrossRef Braathen LR, Kaman T. Human epidermal Langerhans cells induce cellular immune response to trichophytin response in dermatophytosis. Br J Dermatol 1983; 109: 295–300PubMedCrossRef
18.
Zurück zum Zitat Swejgaard E. Humoral antibody responses in the immunopathogenesis of dermatophytosis. Acta Derm Venereol (Stockh.) 1986; 121: 85–91 Swejgaard E. Humoral antibody responses in the immunopathogenesis of dermatophytosis. Acta Derm Venereol (Stockh.) 1986; 121: 85–91
19.
Zurück zum Zitat Calderon RA, Hay RJ. Fungicidal activity of human neutrophils and monocytes on dermatophyte fungi, Trichophyton quinckeanum and Trichophyton rubrum. Immunology 1987; 61: 289–95PubMed Calderon RA, Hay RJ. Fungicidal activity of human neutrophils and monocytes on dermatophyte fungi, Trichophyton quinckeanum and Trichophyton rubrum. Immunology 1987; 61: 289–95PubMed
20.
Zurück zum Zitat Novick NL, Tapia L, Bottone EJ. Invasive Trichophyton rubrum infection in an immunocompromised host: case report and review of the literature. Am J Med 1987; 82: 321–5PubMedCrossRef Novick NL, Tapia L, Bottone EJ. Invasive Trichophyton rubrum infection in an immunocompromised host: case report and review of the literature. Am J Med 1987; 82: 321–5PubMedCrossRef
21.
Zurück zum Zitat Diehl KB. Topical antifungal agents: an update. Am Fam Physician 1996; 54: 1687–92PubMed Diehl KB. Topical antifungal agents: an update. Am Fam Physician 1996; 54: 1687–92PubMed
22.
Zurück zum Zitat Ganzinger U, Stutz A, Petranyi G, et al. Allylamines: topical and oral treatment of dermatomycoses with a new class of antifungal agents. Acta Derm Venereol Suppl (Stockh.) 1986; 121: 155–60 Ganzinger U, Stutz A, Petranyi G, et al. Allylamines: topical and oral treatment of dermatomycoses with a new class of antifungal agents. Acta Derm Venereol Suppl (Stockh.) 1986; 121: 155–60
23.
Zurück zum Zitat Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1992; 126 Suppl. 39: 2–7PubMedCrossRef Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1992; 126 Suppl. 39: 2–7PubMedCrossRef
24.
Zurück zum Zitat Evans EG, James IG, Seaman RA, et al. Does naftifine have anti-inflammatory properties? A double-blind comparative study with 1% clotrimazole/1% hydrocortisone in clinically diagnosed fungal infection of the skin. Br J Dermatol 1993; 129: 437–42PubMedCrossRef Evans EG, James IG, Seaman RA, et al. Does naftifine have anti-inflammatory properties? A double-blind comparative study with 1% clotrimazole/1% hydrocortisone in clinically diagnosed fungal infection of the skin. Br J Dermatol 1993; 129: 437–42PubMedCrossRef
25.
Zurück zum Zitat Nada M, Hanafi S, al-Omari H, et al. Naftifine versus miconazole/hydrocortisone in inflammatory dermatophyte infections. Int J Dermatol 1994; 33: 570–2PubMedCrossRef Nada M, Hanafi S, al-Omari H, et al. Naftifine versus miconazole/hydrocortisone in inflammatory dermatophyte infections. Int J Dermatol 1994; 33: 570–2PubMedCrossRef
26.
Zurück zum Zitat Smith EB, Breneman DL, Griffith RF, et al. Double-blind comparison of naftifine cream and clotrimazole/betamethasone diproprionate cream in the treatment of tinea pedis. J Am Acad Dermatol 1992; 26: 125–7PubMedCrossRef Smith EB, Breneman DL, Griffith RF, et al. Double-blind comparison of naftifine cream and clotrimazole/betamethasone diproprionate cream in the treatment of tinea pedis. J Am Acad Dermatol 1992; 26: 125–7PubMedCrossRef
27.
Zurück zum Zitat Tronnier H. Inflammatory dermatomycoses-comparative study of naftifine and a combination of a corticosteroid and an imidazole derivative. Mykosen 1987; 30: 78–87 Tronnier H. Inflammatory dermatomycoses-comparative study of naftifine and a combination of a corticosteroid and an imidazole derivative. Mykosen 1987; 30: 78–87
28.
Zurück zum Zitat Evans EG, Seaman RA, James IG. Short-duration therapy with terbinafine 1% cream in dermatophyte skin infections. Br J Dermatol 1994; 130: 83–7PubMedCrossRef Evans EG, Seaman RA, James IG. Short-duration therapy with terbinafine 1% cream in dermatophyte skin infections. Br J Dermatol 1994; 130: 83–7PubMedCrossRef
29.
Zurück zum Zitat Smith ES, Fleischer Jr AB, Feldman SR. Nondermatologists are more likely than dermatologists to prescribe antifungal/corticosteroid products: an analysis of office visits for cutaneous fungal infections, 1990–1994. J Am Acad Dermatol 1998; 39: 43–7PubMedCrossRef Smith ES, Fleischer Jr AB, Feldman SR. Nondermatologists are more likely than dermatologists to prescribe antifungal/corticosteroid products: an analysis of office visits for cutaneous fungal infections, 1990–1994. J Am Acad Dermatol 1998; 39: 43–7PubMedCrossRef
30.
Zurück zum Zitat Greenberg HL, Shwayder TA, Bieszk N, et al. Clotrimazole/betamethasone diproprionate: a review of costs and complications in the treatment of common cutaneous fungal infections. Pediatr Dermatol 2002; 19: 78–81PubMedCrossRef Greenberg HL, Shwayder TA, Bieszk N, et al. Clotrimazole/betamethasone diproprionate: a review of costs and complications in the treatment of common cutaneous fungal infections. Pediatr Dermatol 2002; 19: 78–81PubMedCrossRef
31.
Zurück zum Zitat Shaffer MP, Feldman SR, Fleischer Jr AB. Use of clotrimazole/betamethasone diproprionate by family physicians. Fam Med 2000; 32: 561–5PubMed Shaffer MP, Feldman SR, Fleischer Jr AB. Use of clotrimazole/betamethasone diproprionate by family physicians. Fam Med 2000; 32: 561–5PubMed
32.
Zurück zum Zitat Fleischer Jr AB, Feldman SR. Prescription of high-potency corticosteroid agents and clotrimazole-betamethasone dipropionate by pediatricians. Clin Ther 1999; 21: 1725–31PubMedCrossRef Fleischer Jr AB, Feldman SR. Prescription of high-potency corticosteroid agents and clotrimazole-betamethasone dipropionate by pediatricians. Clin Ther 1999; 21: 1725–31PubMedCrossRef
33.
Zurück zum Zitat Railan D, Wilson JK, Feldman SR, et al. Pediatricians who prescribe clotrimazole-betamethasone diproprionate (Lotrisone) often utilize it in inappropriate settings regardless of their knowledge of the drug!!!2019;s potency. Dermatol Online J 2002; 8: 3PubMed Railan D, Wilson JK, Feldman SR, et al. Pediatricians who prescribe clotrimazole-betamethasone diproprionate (Lotrisone) often utilize it in inappropriate settings regardless of their knowledge of the drug!!!2019;s potency. Dermatol Online J 2002; 8: 3PubMed
34.
Zurück zum Zitat Rang HP, Dale MM. Pharmacology. 2nd ed. Hong Kong: Churchill Livingstone, 1991: 510–9 Rang HP, Dale MM. Pharmacology. 2nd ed. Hong Kong: Churchill Livingstone, 1991: 510–9
35.
Zurück zum Zitat Frances C. Practical application of local corticotherapy: topical corticosteroids [in French]. Rev Prat 1990 Feb 21; 40 (6): 527–30PubMed Frances C. Practical application of local corticotherapy: topical corticosteroids [in French]. Rev Prat 1990 Feb 21; 40 (6): 527–30PubMed
36.
Zurück zum Zitat Kragballe K. Topical corticosteroids: mechanisms of action. Acta Derm Venereol Suppl (Stockh.) 1989; 151: 7–10 Kragballe K. Topical corticosteroids: mechanisms of action. Acta Derm Venereol Suppl (Stockh.) 1989; 151: 7–10
37.
Zurück zum Zitat Samsun C, Peets E, Winter-Sperry R, et al. Clotrimazole/betamethasone diproprionate-Lotrisone: an antifungal/steroid combination for treatment of cutaneous dermatophyte infection. In: Maibach HI, Surber C, editors. Topical corticosteroids. Basel: Karger, 1992: 318–34 Samsun C, Peets E, Winter-Sperry R, et al. Clotrimazole/betamethasone diproprionate-Lotrisone: an antifungal/steroid combination for treatment of cutaneous dermatophyte infection. In: Maibach HI, Surber C, editors. Topical corticosteroids. Basel: Karger, 1992: 318–34
38.
Zurück zum Zitat La Grenade L, Vega A, Luke MC. Adverse effects of Lotrisone cream used in infants. Pediatrics 2000; 106: 519–20 La Grenade L, Vega A, Luke MC. Adverse effects of Lotrisone cream used in infants. Pediatrics 2000; 106: 519–20
39.
Zurück zum Zitat Gorani A, Schiera A, Oriani A. Case report: rosacea-like tinea incognitio. Mycoses 2002; 45: 135–7PubMedCrossRef Gorani A, Schiera A, Oriani A. Case report: rosacea-like tinea incognitio. Mycoses 2002; 45: 135–7PubMedCrossRef
40.
Zurück zum Zitat Almeida L, Grossman M. Widespread dermatophyte infection that mimic collagen vascular disease. J Am Acad Dermatol 1990; 23: 855–7PubMedCrossRef Almeida L, Grossman M. Widespread dermatophyte infection that mimic collagen vascular disease. J Am Acad Dermatol 1990; 23: 855–7PubMedCrossRef
41.
Zurück zum Zitat Reynolds RD, Boiko S, Lucky AW. Exacerbation of tinea corporis during treatment with 1% clotrimazole/0.05% betamethasone diproprionate (Lotrisone). Am J Dis Child 1991; 145: 1224–5PubMed Reynolds RD, Boiko S, Lucky AW. Exacerbation of tinea corporis during treatment with 1% clotrimazole/0.05% betamethasone diproprionate (Lotrisone). Am J Dis Child 1991; 145: 1224–5PubMed
42.
Zurück zum Zitat Rosen T, Elewski BE. Failure of clotrimazole-betamethasone diproprionate cream in treatment of Microsporum canis infections. J Am Acad Dermatol 1995; 32: 1050–1PubMedCrossRef Rosen T, Elewski BE. Failure of clotrimazole-betamethasone diproprionate cream in treatment of Microsporum canis infections. J Am Acad Dermatol 1995; 32: 1050–1PubMedCrossRef
43.
Zurück zum Zitat Barkey WF. Striae and persistent tinea corporis related to prolonged use of betamethasone dipropionate 0.05% cream/clotrimazole 1% cream (Lotrisone cream). J Am Acad Dermatol 1987; 17: 518–9PubMedCrossRef Barkey WF. Striae and persistent tinea corporis related to prolonged use of betamethasone dipropionate 0.05% cream/clotrimazole 1% cream (Lotrisone cream). J Am Acad Dermatol 1987; 17: 518–9PubMedCrossRef
44.
Zurück zum Zitat Alston SJ, Cohen BA, Braun M. Persistent and recurrent tinea corporis in children treated with combination antifungal/corticosteroid agents. Pediatrics 2003; 111: 201–3PubMedCrossRef Alston SJ, Cohen BA, Braun M. Persistent and recurrent tinea corporis in children treated with combination antifungal/corticosteroid agents. Pediatrics 2003; 111: 201–3PubMedCrossRef
46.
Zurück zum Zitat Jacobs JA, Kolbach DN, Vermeulen AH, et al. Tinea incognito due to Trichophytom rubrum after local steroid therapy. Clin Infect Dis 2001; 33: E142–144CrossRef Jacobs JA, Kolbach DN, Vermeulen AH, et al. Tinea incognito due to Trichophytom rubrum after local steroid therapy. Clin Infect Dis 2001; 33: E142–144CrossRef
47.
Zurück zum Zitat Solomon BA, Glass AT, Rabbin PE. Tinea incognito and !!!2018;over-the-counter!!!2019; potent topical steroids. Cutis 1996; 58: 295–6PubMed Solomon BA, Glass AT, Rabbin PE. Tinea incognito and !!!2018;over-the-counter!!!2019; potent topical steroids. Cutis 1996; 58: 295–6PubMed
48.
Zurück zum Zitat Toler T. Tinea incognito and over-the-counter potent topical steroids [letter]. Cutis 1997; 59 (4): 295–6 Toler T. Tinea incognito and over-the-counter potent topical steroids [letter]. Cutis 1997; 59 (4): 295–6
49.
Zurück zum Zitat Feder Jr HM. Tinea incognito misdiagnosed as erythema migrans. N Engl J Med 2000; 343 (1): 69PubMedCrossRef Feder Jr HM. Tinea incognito misdiagnosed as erythema migrans. N Engl J Med 2000; 343 (1): 69PubMedCrossRef
50.
Zurück zum Zitat Elgart ML. Tinea incognito: an update on Majocchi granuloma. Dermatol Clin 1996; 14 (1): 51–5PubMed Elgart ML. Tinea incognito: an update on Majocchi granuloma. Dermatol Clin 1996; 14 (1): 51–5PubMed
51.
Zurück zum Zitat Chen AW, Kuo KWL, Chen JS, et al. Dermatophyte pseudomycetoma: a case report. Br J Dermatol 1993; 129: 729–32PubMedCrossRef Chen AW, Kuo KWL, Chen JS, et al. Dermatophyte pseudomycetoma: a case report. Br J Dermatol 1993; 129: 729–32PubMedCrossRef
52.
Zurück zum Zitat Degreef H, Dooms-Goossens A. The new corticosteroids: are they effective and safe? Dermatol Clin 1993; 11: 155–60PubMed Degreef H, Dooms-Goossens A. The new corticosteroids: are they effective and safe? Dermatol Clin 1993; 11: 155–60PubMed
53.
Zurück zum Zitat Adams BB, Sheth PB. Perianal ulcerations from topical steroid use. Cutis 2002; 69: 67–8PubMed Adams BB, Sheth PB. Perianal ulcerations from topical steroid use. Cutis 2002; 69: 67–8PubMed
54.
Zurück zum Zitat Korting HC, Kerscher MJ, Schafer-Korting M. Topical glucocorticoids with improved benefit/risk ratio: do they exist? J Am Acad Dermatol 1992; 27: 87–92PubMedCrossRef Korting HC, Kerscher MJ, Schafer-Korting M. Topical glucocorticoids with improved benefit/risk ratio: do they exist? J Am Acad Dermatol 1992; 27: 87–92PubMedCrossRef
55.
Zurück zum Zitat Erbagci Z, Balci I, Erkilic S, et al. Cutaneous hyalohyphomycosis and onychomycosis caused by Onychocola canadensis: report of the first case from Turkey. J Dermatol 2002; 29: 522–8PubMed Erbagci Z, Balci I, Erkilic S, et al. Cutaneous hyalohyphomycosis and onychomycosis caused by Onychocola canadensis: report of the first case from Turkey. J Dermatol 2002; 29: 522–8PubMed
56.
Zurück zum Zitat Raab W. Behandlung von Mykosen mit Corticoid-haltigen Praparaten. Hautarzt 1975; 26: 349–51PubMed Raab W. Behandlung von Mykosen mit Corticoid-haltigen Praparaten. Hautarzt 1975; 26: 349–51PubMed
57.
Zurück zum Zitat Raab W. Antimycotic substances and corticosteroids [in German]. Arch Klin Exp Dermatol 1968; 231: 250–63PubMed Raab W. Antimycotic substances and corticosteroids [in German]. Arch Klin Exp Dermatol 1968; 231: 250–63PubMed
58.
Zurück zum Zitat Raab W, Hogl F. The influence of glucocorticoids on the inhibition of enzymatic activities exerted by antifungal imidazole derivatives [in German]. Mykosen 1982; 25: 303–14PubMedCrossRef Raab W, Hogl F. The influence of glucocorticoids on the inhibition of enzymatic activities exerted by antifungal imidazole derivatives [in German]. Mykosen 1982; 25: 303–14PubMedCrossRef
59.
Zurück zum Zitat Hogl F, Raab W. The influence of glucocorticoids on the membrane disrupting activity of antifungal imidazole derivatives [author!!!2019;s translation in German]. Mykosen 1982; 25 (6): 315–20PubMedCrossRef Hogl F, Raab W. The influence of glucocorticoids on the membrane disrupting activity of antifungal imidazole derivatives [author!!!2019;s translation in German]. Mykosen 1982; 25 (6): 315–20PubMedCrossRef
60.
Zurück zum Zitat Hogl F, Raab W. The influence of steroids on the antifungal and antibacterial activities of imidazole derivatives [author!!!2019;s translation in German]. Mykosen 1980; 23 (8): 426–39PubMedCrossRef Hogl F, Raab W. The influence of steroids on the antifungal and antibacterial activities of imidazole derivatives [author!!!2019;s translation in German]. Mykosen 1980; 23 (8): 426–39PubMedCrossRef
61.
Zurück zum Zitat Raab W, Gmeiner B. Interactions between econazole, a broad-spectrum antimicrobic substance, and topically active glucocorticoids. Dermatologica 1976; 153: 14–22PubMedCrossRef Raab W, Gmeiner B. Interactions between econazole, a broad-spectrum antimicrobic substance, and topically active glucocorticoids. Dermatologica 1976; 153: 14–22PubMedCrossRef
62.
Zurück zum Zitat Raab W, Killer S. Haloprogin: its effects in the presence of glucocorticoids and neomycin [in German]. Z Hautkr 1975; 50: 499–505PubMed Raab W, Killer S. Haloprogin: its effects in the presence of glucocorticoids and neomycin [in German]. Z Hautkr 1975; 50: 499–505PubMed
63.
Zurück zum Zitat Katz HI, Bard J, Cole GW, et al. SCH 370 (clotrimazole-betamethasone dipropionate) cream in patients with tinea cruris or tinea corporis. Cutis 1984; 34: 183–8PubMed Katz HI, Bard J, Cole GW, et al. SCH 370 (clotrimazole-betamethasone dipropionate) cream in patients with tinea cruris or tinea corporis. Cutis 1984; 34: 183–8PubMed
64.
Zurück zum Zitat Shankland GS, Richardson MD. Comparative in-vivo activity of clotrimazole and a clotrimazole/hydrocortisone combination in the treatment of experimental dermatophytosis in guinea pigs. J Antimicrob Chemother 1990; 25: 825–30PubMedCrossRef Shankland GS, Richardson MD. Comparative in-vivo activity of clotrimazole and a clotrimazole/hydrocortisone combination in the treatment of experimental dermatophytosis in guinea pigs. J Antimicrob Chemother 1990; 25: 825–30PubMedCrossRef
65.
Zurück zum Zitat Shankland GS, Richardson MD. Treatment of experimental dermatophytosis in guinea pigs: a comparative study of bifonazole and a bifonazole-hydrocortisone combination. Mycoses 1989; 32: 139–44PubMedCrossRef Shankland GS, Richardson MD. Treatment of experimental dermatophytosis in guinea pigs: a comparative study of bifonazole and a bifonazole-hydrocortisone combination. Mycoses 1989; 32: 139–44PubMedCrossRef
66.
Zurück zum Zitat Wachs GN, Maibach HI. Co-operative double-blind trial of an antibiotic/corticoid combination in impetiginized atopic dermatitis. Br J Dermatol 1976; 95: 323–8PubMedCrossRef Wachs GN, Maibach HI. Co-operative double-blind trial of an antibiotic/corticoid combination in impetiginized atopic dermatitis. Br J Dermatol 1976; 95: 323–8PubMedCrossRef
67.
Zurück zum Zitat Pazzaglia A. Therapeutic effects and tolerance of an extempore combination of an antibacterial, an anti-inflammatory, and an antimycotic cream in skin diseases of various origins. Pharmatherapeutica 1985; 4: 122–5PubMed Pazzaglia A. Therapeutic effects and tolerance of an extempore combination of an antibacterial, an anti-inflammatory, and an antimycotic cream in skin diseases of various origins. Pharmatherapeutica 1985; 4: 122–5PubMed
68.
Zurück zum Zitat Nolting S, Rogalla K. Double-blind comparison of miconazole/corticosteroid combination versus miconazole in inflammatory dermatomycoses. Int J Dermatol 1995; 34: 125–8PubMedCrossRef Nolting S, Rogalla K. Double-blind comparison of miconazole/corticosteroid combination versus miconazole in inflammatory dermatomycoses. Int J Dermatol 1995; 34: 125–8PubMedCrossRef
69.
Zurück zum Zitat Carbone F. Combination of an antiinflammatory steroid, an antibacterial agent an antifungal agent. Clin Trials J 1985; 22: 158–64 Carbone F. Combination of an antiinflammatory steroid, an antibacterial agent an antifungal agent. Clin Trials J 1985; 22: 158–64
70.
Zurück zum Zitat Bowring ARW, Mackay D, Taylor FR. The treatment of napkin dermatitis: a double-blind comparison of two steroid-antibiotic combinations. Pharmatherapeutica 1984; 3: 613–7PubMed Bowring ARW, Mackay D, Taylor FR. The treatment of napkin dermatitis: a double-blind comparison of two steroid-antibiotic combinations. Pharmatherapeutica 1984; 3: 613–7PubMed
71.
Zurück zum Zitat Szarmach H, Weuta H, Stepka L. Indikationsabgrenzung zwischen Clotrimazol/Hydrocortison und seining beiden Komponenten. Ein doppelblinde Studie. Arzneimittelforschung 1984; 34: 927–30PubMed Szarmach H, Weuta H, Stepka L. Indikationsabgrenzung zwischen Clotrimazol/Hydrocortison und seining beiden Komponenten. Ein doppelblinde Studie. Arzneimittelforschung 1984; 34: 927–30PubMed
72.
Zurück zum Zitat Wortzel MH. A double-blind study comparing the superiority of a combination antifungal (clotrimazole)/steroidal (betamethasone dipropianate) product. Cutis 1982; 30: 258–61PubMed Wortzel MH. A double-blind study comparing the superiority of a combination antifungal (clotrimazole)/steroidal (betamethasone dipropianate) product. Cutis 1982; 30: 258–61PubMed
73.
Zurück zum Zitat Pariser RJ, Pariser DM. Clinical and mycological effect of clotrimazole/betamethasone dipropionate cream versus ketoconazole cream in patients with tinea cruris. J Dermatol Treat 1995; 6: 173–7CrossRef Pariser RJ, Pariser DM. Clinical and mycological effect of clotrimazole/betamethasone dipropionate cream versus ketoconazole cream in patients with tinea cruris. J Dermatol Treat 1995; 6: 173–7CrossRef
74.
Zurück zum Zitat Elewski BE, Jones T, Zaias N. Comparison of an antifungal agent used alone with an antifungal used with a topical steroid in inflammatory tinea pedis. Cutis 1996; 58: 305–7PubMed Elewski BE, Jones T, Zaias N. Comparison of an antifungal agent used alone with an antifungal used with a topical steroid in inflammatory tinea pedis. Cutis 1996; 58: 305–7PubMed
75.
Zurück zum Zitat Raab W. Effects of local corticosteroids in skin infections. Dermatologica 1976; 152 Suppl. 1: 67–79PubMedCrossRef Raab W. Effects of local corticosteroids in skin infections. Dermatologica 1976; 152 Suppl. 1: 67–79PubMedCrossRef
76.
Zurück zum Zitat Fleisher AB, Feldman SR. Prescribing and cost analysis of treatments of cutaneous fungal infections: reply [letter]. J Am Acad Dermatol 1999; 40: 1014–5CrossRef Fleisher AB, Feldman SR. Prescribing and cost analysis of treatments of cutaneous fungal infections: reply [letter]. J Am Acad Dermatol 1999; 40: 1014–5CrossRef
Metadaten
Titel
Topical Therapy for Dermatophytoses
Should Corticosteroids be Included?
verfasst von
Dr Zulal Erbagci
Publikationsdatum
01.12.2004
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 6/2004
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200405060-00002

Weitere Artikel der Ausgabe 6/2004

American Journal of Clinical Dermatology 6/2004 Zur Ausgabe

Acknowledgments

Acknowledgment

Adis Drug Evaluation

Pimecrolimus

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.